Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Asynchronous antigen expression in B lineage acute lymphoblastic leukemia.

C A Hurwitz1, M R Loken, M L Graham

  • 1Johns Hopkins Oncology Center, Pediatric Oncology, Baltimore, MD 21205.

Blood
|July 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children's Oncology Group Report.

Leukemia·2024
Same author

CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment.

Blood cancer journal·2017
Same author

MIM regulates the trafficking of bone marrow cells via modulating surface expression of CXCR4.

Leukemia·2016
Same author

MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors.

Cell death and differentiation·2015
Same author

Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031.

Leukemia·2014
Same author

Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children's Oncology Group Study AALL0031.

Leukemia·2014

Most B lineage acute lymphocytic leukemia (ALL) cases show asynchronous expression of cell surface markers, differing from normal B cell development. This suggests ALL involves asynchronous maturation rather than a simple arrest at a specific developmental stage.

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • B lineage acute lymphocytic leukemia (ALL) is a significant hematologic malignancy.
  • Understanding the cell surface phenotypes of ALL is crucial for diagnosis and understanding its biology.
  • Normal B lymphocyte development follows a defined sequence of antigen expression.

Purpose of the Study:

  • To compare the cell surface phenotypes of B lineage ALL cases with normal B lymphocyte development stages.
  • To investigate the concept of 'developmental asynchrony' in B lineage ALL.
  • To explore whether ALL represents cells arrested at a specific developmental stage.

Main Methods:

  • Evaluated cell surface marker expression (HLA-DR, CD19, CD34, CD10, CD20, CD22) in 113 B lineage ALL cases using indirect one-color immunofluorescence.

Related Experiment Videos

  • Performed pairwise comparisons of antigen expression on leukemic cells.
  • Compared complete immunophenotypes of ALL cases with normal B-cell developmental stages, confirmed with two-color immunofluorescence.

    • Main Results:

    • No correlations were observed for paired antigen expression on leukemic cells relative to normal B cell development.
    • Sixteen distinct immunophenotypes not found in normal marrow were identified in ALL cases.
    • At least 78% of B lineage ALL cases exhibited asynchronous combinations of B lymphoid-associated differentiation antigens.

    Conclusions:

    • The majority of B lineage leukemias display 'developmental asynchrony' compared to normal B cells.
    • ALL does not appear to represent cells arrested at the stage of leukemogenesis.
    • B lineage ALL may involve asynchronous maturation of leukemic blasts relative to normal development.